C11864: Novel Artemisinin Analog Antimalarial Drugs
Novelty:
The inventors have created several semisynthetic analogs of artemisinin with antimalarial properties.
Value Proposition:
In 2010, malaria affected over 216 million people, and while treatments for malaria exist, malaria parasites have grown resistant to several of the commonly used, quinoline-based drugs. Artemisinin is known for its antimalarial properties and is currently used as a component in the common antimalaria combination therapy (ACT). This invention is several semisynthetic analogs of artemisinin for use in novel antimalarial drugs. Advantages of this invention include:
- Treatment of malaria where malaria parasites have become resistant to current treatments
- Compatible with ACT, commonly used in areas in which malaria is epidemic
- Applications to the treatment of toxoplasmic infections, subjects afflicted with psychiatric conditions associated with toxoplasmic infection, and subjects afflicted with cancer
Technical Details:
Johns Hopkins researchers have developed semisynthetic analogs of artemisinin with antimalarial properties. Researchers have identified several effective trioxane thioacetal artemisinin derivatives for use in ACT. These drugs have demonstrated efficacy in mouse models and have the potential to treat malaria parasites that are resistant to currently used drugs. These may have further applications in the treatment of toxoplasmic infections, subjects afflicted with psychiatric conditions associated with toxoplasmic infection, and subjects afflicted with cancer.
Looking for Partners:
To develop and commercialize technology as an alternate antimalarial therapy.
Stage of Development:
Pre-clinical
Data Availability:
Mouse data
Publications/Associated Cases:
US-2015-0031677; PMC3460521
